Pomalidomide

CMS has selected 15 new drugs for the next round of Medicare Part D price negotiations, according to a press release from HHS.

The combination of belantamab mafodotin, pomalidomide and dexamethasone extended PFS compared with standard care for patients with relapsed or refractory multiple myeloma, according to a topline data announcement.

The combination of mezigdomide and dexamethasone exhibited activity among patients with heavily pretreated multiple myeloma, according to study results published in The New England Journal of Medicine.

A phase 3 trial of ciltacabtagene autoleucel for adults with relapsed or refractory multiple myeloma met its primary endpoint, according to the agent’s manufacturer.

Belantamab mafodotin-blmf failed to extend PFS compared with pomalidomide and dexamethasone for adults with relapsed or refractory multiple myeloma, according to topline data from a confirmatory trial released by the agent’s manufacturer.

Idecabtagene vicleucel extended PFS compared with standard regimens for adults with advanced multiple myeloma, according to topline data released by the agent’s manufacturer.

Although efforts have been made to increase sharing of individual participant data from clinical trials, data from many oncology clinical trials that support FDA approval of anticancer therapies remain unavailable to researchers.

The addition of daratumumab to pomalidomide and dexamethasone extended PFS among patients with relapsed or refractory multiple myeloma who were refractory to lenalidomide, according to a study presented at ASH Annual Meeting and Exposition.

Isatuximab plus pomalidomide and low-dose dexamethasone continued to show significant improvement in time to next treatment and PFS2 compared with pomalidomide and dexamethasone in relapsed or refractory multiple myeloma, according to updated results from the ICARIA-MM study.